AMAG Pharmaceuticals, Inc. (AMAG) Announces Patent Term Extension For Ferumoxytol In The U.S.
6/6/2014 9:20:07 AM
WALTHAM, Mass., June 6, 2014 (GLOBE NEWSWIRE) -- AMAG Pharmaceuticals, Inc. (Nasdaq:AMAG) today announced that the United States Patent and Trademark Office (USPTO) has issued a U.S. patent term extension certificate extending the term of U.S. Patent No. 6,599,498 by 1,209 days. With this extension the '498 patent will now expire June 30, 2023. This patent is directed to reduced polysaccharide iron oxide complexes, including ferumoxytol. The '498 patent is listed in Approved Drug Products with Therapeutic Equivalence Evaluations (commonly known as the Orange Book), published by the United States Food and Drug Administration.
Help employers find you! Check out all the jobs and post your resume.
comments powered by